Bionano Genomics, Inc. BNGO

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
35/100
Developing

Ranked against 61 peers in Medical Instruments & Supplies

About Bionano Genomics, Inc.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr … Full BNGO analysis →

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.96). Improving FCF margin signals compounding operational leverage.
  • Expanding Operating Margin Operating margin trend is positive (score 0.96). Margin expansion confirms commercial leverage is building.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.25). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.22). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
29
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where BNGO ranks in Medical Instruments & Supplies

Bionano Genomics, Inc. ranks #46 of 62 scored companies in Medical Instruments & Supplies by moat score — the top 74%. The widest moat in the group is Intuitive Surgical, Inc. (ISRG) at 86/100.

# Company Moat score Rating
42 NexGel, Inc NXGL 38/100 Developing
43 NexGel, Inc Warrant NXGLW 38/100 Developing
44 Harvard Bioscience, Inc. HBIO 37/100 Developing
45 LUCY LUCY 35/100 Developing
46 Bionano Genomics, Inc. BNGO 35/100 Developing
47 Anteris Technologies Global Cor AVR 34/100 Developing
48 Stereotaxis, Inc. STXS 33/100 Developing
49 OraSure Technologies, Inc. OSUR 33/100 Developing
50 LUCYW LUCYW 31/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How BNGO scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 29 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 19 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 56 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 51 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 30 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 17 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding BNGO's moat

What is Bionano Genomics, Inc.'s moat score?

Bionano Genomics, Inc. (BNGO) scores 35 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #46 of 62 scored companies in Medical Instruments & Supplies, the top 74%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Medical Instruments & Supplies. Its strongest defense is FCF Quality & Cash Conversion (56/100) and its weakest is Growth Durability (17/100).

How does Bionano Genomics, Inc. compare with other Medical Instruments & Supplies companies?

Bionano Genomics, Inc. ranks #46 of 62 scored companies in Medical Instruments & Supplies by moat score. The widest moat in Medical Instruments & Supplies is Intuitive Surgical, Inc. (ISRG) at 86/100. The companies ranked closest are LUCY (LUCY) at 35 just above it and Anteris Technologies Global Cor (AVR) at 34 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Medical Instruments & Supplies. The defenses are then weighted to produce the overall score out of 100.

Why is Bionano Genomics, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Bionano Genomics, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and BNGO scores: Pricing Power & Consumable Moat (29), R&D Pipeline & Capital Returns (19), FCF Quality & Cash Conversion (56), Commercial Execution (51), Capital Structure & Resilience (30), Growth Durability (17). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000